Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal intelligence from Strategic Transactions.
Employing a hub-and-spoke model to launch biotechs focused on monogenetic disorders, BridgeBio Pharma unveiled a new subsidiary, Origin Biosciences,...